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Background: CD34+ progenitor cells comprise both hematopoietic and endothelial progenitor cells. Recent studies
suggest that circulating endothelial progenitor cells are recruited into the angiogenic vascular system of several
cancers, including pancreatic carcinoma, and that they correlate with clinical progress. However, whether
endothelial progenitor cell mobilization occurs in response to cytokine release by tumor cells is still unclear.
Methods: The chemotactic- and/or differentiating-activities of the poorly-differentiated pancreatic carcinoma cell
line PT45, and of the immortal H6c7 cell line, a line of near-normal pancreatic duct epithelial cells, on endothelial
progenitor cells were investigated in vitro using circulating CD34+ as model.
Results: The study showed that Vascular Endothelial Growth Factor produced by PT45 cells and, at lesser extent, by
H6c7 cells, predominantly chemoattract peripheral blood CD34+ expressing the type 2 relative receptor. Addition of
PT45-conditioned medium to CD34+ cells, cultured under conditions supporting myeloid cell development, diverted
the differentiation of a subset of these progenitor cells into cells expressing endothelial cell markers, such as CD146,
CD105, VE-cadherin and von Willebrand Factor-related antigen. Moreover, these endothelial-like cells formed capillary
networks in vitro, chiefly through the release of Angiopoietin-1 by PT45 cells.
Conclusions: The results demonstrate that pancreatic-carcinoma cells potentially attract circulating endothelial
progenitor cells to the tumor site, by releasing high levels of pro-angiogenic factors such as Vascular Endothelial
Growth Factor and Angiopoietin-1, and may direct the differentiation of these cell subsets of the CD34+ cell population
into endothelial cells; the latter cells may become a component of the newly-formed vessels, contributing to
angiogenesis-mediated tumor growth and metastasis.
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Tumor neoangiogenesisBackground
It is well known that, in order to develop in size and
metastatic potential, tumors must make an "angiogenic
switch"; they achieve this by perturbing the local
balance of pro-angiogenic and anti-angiogenic factors
[1]. When positive angiogenic regulators overcome the
effect of negative angiogenic molecules, the tumor
acquires angiogenic capability, leading to the forma-
tion of new blood vessels.* Correspondence: graziella.bellone@unito.it
1Department of Medical Sciences, University of Turin, Turin, Italy
Full list of author information is available at the end of the article
© 2013 Vizio et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orTumor cells may induce angiogenesis directly, by
releasing pro-angiogenic factors, and/or indirectly, by
attracting inflammatory cells that, in turn, release angio-
genic stimuli [2]. The number of factors known to be
capable of eliciting an angiogenic response is steadily
increasing. Vascular Endothelial Growth Factor (VEGF)
is considered a master regulator of the angiogenic
cascade, and is thought to promote endothelial cell
differentiation, migration, proliferation, and survival [3].
The finding that a number of malignant human tumors,
including lung, breast, gastrointestinal tract, ovary, and
colon, produce VEGF [4-8], and that the inhibition ofd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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growth in vivo [9], point to its possessing clinical signifi-
cance in tumor growth.
Pancreatic carcinoma is a biologically-aggressive
tumor that has an early propensity to spread locally
and metastasize distally. While not grossly vascular,
this tumor often exhibits enhanced foci of endothelial
cell proliferation, and over-expresses multiple pro-
angiogenic factors [10,11]. In particular, a positive cor-
relation between blood vessel density, tumor VEGF-A
isoform levels, and disease progression has been re-
ported in pancreatic carcinoma [12-14].
The formation of new capillaries to provide an oxygen
supply for tumors was, until recently, believed to be me-
diated by the sprouting or co-option of pre-existing
neighboring vessels [15].
However, increasing evidence now suggests that circu-
lating endothelial progenitor cells (EPC), normally in-
volved in maintaining vascular integrity, can also home
in to the tumor site and contribute to the de novo
formation of blood vessels [16].
In previous studies we found that VEGF expression in
pancreatic carcinoma cell lines is both high and inversely
correlated with differentiation status [10]. Moreover,
EPC and VEGF-A plasma levels were found to be signifi-
cantly elevated in the blood of pancreatic carcinoma
patients, to be positively associated with disease stage, and
inversely associated with overall survival [17]. These finding
suggest that microenvironmental conditions favoring mo-
bilization of EPC, which are key contributors to the early
steps in neoplastic vascularization [18], might enable the
tumor to grow and metastasize faster. However, there is on-
going debate about the distribution, contribution, origin,
and differentiation of EPC in tumor vasculogenesis.
The present research aimed to investigate the ability of
pancreatic carcinoma cells to attract and skew the differen-
tiation of CD34+ progenitor cells toward endothelial cells,
by releasing pro-angiogenic factors. We show that PT45
cells, as normal pancreatic ductal epithelial cells, promote
the recruitment of CD34+ cells. Moreover, when cultured
under conditions that facilitate myeloid-cell development,
CD34+ cells are instead redirected by the tumor to differen-
tiate into endothelial cells. The resulting cells resemble
endothelial cells phenotypically, as well as functionally,
as is shown by the fact they can be stimulated to
reorganize into cord structures. Tumor-derived VEGF
contributed significantly to the chemoattractant activity,
whereas Angiopoietin (Angio)-1 chiefly provided the in-
structive differentiation signal.
Materials and methods
Ethics Statement
The Hemocomponent Production and Validation Center
(Centro per la Produzione e Validazione di Emoprodotti,CPVE) (Turin, Italy) Ethics Committee has waived the
need for consent, due to the fact the blood donor mater-
ial used was fully anonymized. The study did not involve
human beings directly and, according to article 2 comma
I, letter a) and article 6 of Italian Legislative Decree
dated 24. 06. 2003, no. 211, and article 1, comma I of
Italian Ministry of Health Decree dated 12. 05. 2006, did
not require an opinion from the Ethical Committee.
Cell lines
The pancreatic-cell line PT45 (kindly provided by Dr.
M.F. Di Renzo, Department of Biomedical Sciences and
Human Oncology, University of Turin, Italy) [19] was
grown in RPMI 1640 medium supplemented with 10%
fetal calf serum (FCS) (Merck Millipore, Billerica, MA).
The cell line was routinely screened for mycoplasma
contamination, using the Hoechst dye H33258 (Sigma
Aldrich, St. Louis, MO, USA). Immortalized human
pancreatic ductal epithelial cells HPDE6-E6E7 (H6c7),
established after transduction of the HPV16-E6E7 genes
into primary cultures of normal pancreatic duct epithe-
lial cells, were generously provided by Dr. Ming-Sound
Tsao, (Ontario Cancer Institute/Princess Margaret Hos-
pital, University Health Network, Toronto, Canada) [20].
The cell line demonstrates a near-normal genotype and
phenotype of pancreatic duct epithelial cells [21]. The
H6c7 cells were grown in serum free Keratinocyte Basal
Medium (KBM) fortified with growth factors, cytokines,
and supplements (SingleQuots™ Kit) (Lonza Group Ltd,
Basel, Switzerland).
In order to obtain serum-free conditioned medium (CM),
PT45 and H6c7 cells were trypsinized, extensively washed
with phosphate-buffered saline (PBS), and seeded at 3×105/
ml, in 5 ml of serum-free RPMI 1640 medium containing
0.25% fatty-acid-free bovine serum albumin fraction V
(Sigma Aldrich) and KBM, respectively. After 48-hour
incubation in a humidified atmosphere containing 5% CO2,
CM was collected after centrifugation, and stored at -20°C
until use.
Human umbilical vein endothelial cells (HUVEC)
HUVEC were obtained from Lonza Group Ltd and
propagated in EndoGRO medium (Merck Millipore).
Isolation of circulating CD34+ progenitor cells
Low-density peripheral blood mononuclear cells (PBMC)
were isolated from normal buffy coats received from the
CPVE, by centrifugation at 250 g over Ficoll-Hypaque.
CD34+ cells were purified using the CD34-isolation mini-
MACS (magnetic cell sorting) kit (Miltenyi, Bergisch
Gladbach, Germany) or the EasySep human CD34+ selec-
tion kit (StemCell Technologies, Vancouver, BC, Canada),
following the manufacturers' directions. In both cases, the
Table 1 Primer sequences for housekeeping, cytokine
and endothelial marker quantification by real time
RT-PCR
Primer set GenBank Primer sequence RT-PCR
Accession # E (%)
β-actin NM_001101 FW -GCG AGA AGA
TGA CCC AGA TC-
RW -GGA TAG CAC
AGC CTG GAT AG-
100
VEGF-A NM_001025366 FW -ATG AGG ACA
CCG GCT CTG ACC A-
RW -AGG CTC CTG
AAT CTT CCA GGC A-
94.5
Angio-1 NM_001146 FW -GAG GCA CGG
AAG GAG TGT GCT G-
RW -CGG CGC TGA
TTG CTG CAC CCT A-
92.0
Angio-2 NM_001147 FW -AAA AGC TGA
CAC AGC CCT CCC A-
RW -ACT GCT GTG TTC
TCT CCA GGC A-
86.0
CXCL12 NM_000609 FW -ATG CCC ATG
CCG ATT CTT CG-
RW -GCC GGG CTA
CAA TCT GAA GG-
100
VE-cadherin NM_001795 FW -GGT CCC TGA
ACG CCC TGG TAA-
RW -GGA GTG GAG TAT
GGA GTT GGA GCA-
95.5
von Willebrand
Factor (vWF)
NM_000552 FW -GCC TGC TTC
TGC GAC ACC ATT G-
RW -GCC ACT CAC ACT
CAT ACC CGT TCT-
96.2
Flt1 (VEGF-R1) NM_002019 FW -CAC GCA GGA
CCA GTT TGA TTG AG-
RW -GCT AGA GGA CTC
CCG AGA TGT TG-
96.7
Flk-1/KDR(VEGF-
R2)
NM_002253 FW -GCA GGG GAC
AGA GGG ACT TG-
RW -GAG GCC ATC
GCT GCA CTC A
95.3
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tometry, and was in the 89%-98% range.
RNA extraction and real time reverse transcription
(RT)-PCR
RNA was extracted from PT45 cells, H6c7 cells, 19-day-
cultured CD34+ cells in the absence or presence of
PT45-CM, and from appropriate positive controls, com-
prising the colon carcinoma cell line DLD-1, the hepato-
cellular carcinoma cell line HepG2, bone marrow (BM)
stroma, and HUVEC, using TRIzol Reagent (Invitrogen,
Carlsbad, CA) and following the manufacturer’s instruc-
tions. To remove traces of genomic DNA, total RNA
(3 μg) was treated with DNase I (Invitrogen) and
reverse-transcribed to cDNA, using SuperScript II Re-
verse Transcriptase (Invitrogen). Lastly, cDNA speci-
mens were diluted with 130 μl of H2O.
Real Time RT-PCR analysis was run on the iCycler iQ
system (Bio-Rad, Hercules, CA) by the SYBR green I dye
detection method. Amplification of β-actin, VEGF-A,
Angio-1, Angio-2, SDF-1A (CXCL12), VE-cadherin, von
Willebrand factor (vWF), VEGF receptor (R)-1 (flt-1) and
VEGFR-2 (flk-1/KDR) transcripts was run in duplicate,
in a PCR optical 96-well reaction plate (Bio-Rad); the
PCR mixture in each well contained cDNA correspond-
ing to 100 ng of total RNA, the relevant sequence-
specific primers (150 nM for β-actin and 300 nM for
the other cytokines) and 1X iQ SYBR Green Supermix
(Bio-Rad). Table 1 lists primer sequences, designed using
Beacon Designer 5 Software (Bio-Rad) to be cDNA spe-
cific, and to work under equivalent reaction conditions.
Primers were synthesized by Invitrogen and reconstituted
in nuclease-free water before use. Negative PCR controls
without cDNA template, and a positive control sample
with a known cycle threshold value (Ct), were included
in each assay. Optimized thermal cycling conditions were
as follow: 5 min at 95°C followed by 40 cycles of 15 s at
95°C and 1 min at 60°C (two-step PCR). Specificity of
the PCR products was confirmed by the melting curve
program at the end of the reaction (55°C to 95°C with
a heating rate of 0.5°C/10 sec and continuous fluores-
cence measurements). PCR efficiency (E) was deter-
mined by the method described by Ramakers et al. [22]
using the iCycler iQ software. For each sample, the Ct
was acquired using the Fit Point Method [23]. Mean
normalized gene expression (MNE) was calculated from
the following formula: NE = Ereference
Ct reference/Etarget
Ct target. The statistical significance of the difference in
mRNA expression of the receptors examined, in
PT45-CM treated- and untreated-CD34+ cells, was ana-
lyzed using the Relative Expression Software Tool (REST)
for group-wise comparison, and statistical analysis of
relative expression results in real-time PCR [24]. This
software package calculates an expression ratio relative tothe control group (untreated-CD34+ cells) normalized to
a reference gene (β-actin). The mRNA expression data
for β-actin showed no significant difference between
untreated- and PT45-CM treated- CD34+ cells. The ex-
pression ratio (R) is: R = Etarget
ΔCt target (mean untreated-mean
treated sample)/Ereference
ΔCt reference (mean untreated-mean treated
sample).
Evaluation of VEGF-A, CXCL12, Angio-1, and Angio-2
Secreted levels of VEGF-A, CXCL12, Angio-1, and Angio-2
were determined in cell-free CM from the pancreatic-
carcinoma cell lines PT45 and H6c7, using commercially-
available ELISA kits (R&D Systems, Minneapolis, MN, and
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ufacturers’ directions. The minimum detectable doses were
below 9 pg/ml for VEGF-A, below 18 pg/ml for CXCL12,
below 30 pg/ml for Angio-1, and below 10 pg/ml for
Angio-2.
Cell migration assay
Cell migration assays were run in transwell plates (8 μm
pore size, Costar, Cambridge, MA). Either CD34+ or
HUVEC cell suspension (3×104 cells/ml) was added to
the upper compartment of the transwell chamber. 30%
of PT45- or of H6c7-CM, as such or pre-treated with
neutralizing polyclonal goat antibodies against VEGF-A
(Chemicon International, Temecula, CA) and Angio-1
(Sigma Aldrich), or with appropriate irrelevant antibody
as control, was added to the lower well of the transwell
chamber as chemoattractant. In selected experiments,
CD34+ cells were also pretreated with an anti-human
VEGFR-1/Flt-1 polyclonal goat antibody blocking receptor-
ligand interaction (25 μg/ml) (R&D Systems). The cham-
bers were incubated for 24 h at 37°C, 5% CO2. After
removing the cells from the upper side of the mem-
brane, with a cotton swab, migrated cells were fixed and
stained with crystal violet dye. Stained cells were visual-
ized and quantified by counting cells in three high-
power fields (100X). Data are shown as means ± SE from
three/six separate series of assays.
Proliferation assay
CD34+ cells were seeded in triplicate at a concentration
of 5×104 cells/well in 96-well plates, in RPMI 1640
medium containing 10% FCS, in the absence or presence
of 30% of either PT45-CM or H6c7-CM. 50 ng/ml of
human recombinant Stem Cell Factor (SCF) and Fms-
related tyrosine kinase (FLT)-3 Ligand (PeproTech,
Rocky Hill, NJ) was used as control, to activate stem-cell
and immature-progenitor-cell cycling. To determine
DNA synthesis, after 20 hr incubation, cells were pulsed
with triziated-Thymidine (3H)-TdR (Perkin Elmer, 1 μCi/
well) for a further 4 hr. Cellular DNA was collected
on glass fiber filters, and 3H-TdR incorporation was
measured in a β-counter. Results are expressed as me-
dian cpm (count per minute) (range) of two separate
experiments.
Differentiation of CD34+ cells
To determine the effect of tumor-derived soluble factors
on CD34+ cell differentiation, normal peripheral blood
CD34+ progenitor cells, isolated immunomagnetically as
described above, were resuspended in Iscove medium
(Merck Millipore) containing 20% FCS, 10 ng/ml re-
combinant Interleukin (IL)-3, 10 ng/ml SCF, and 50
ng/ml Granulocyte-Macrophage Colony Stimulating Fac-
tor (GM-CSF) (PeproTech); they were then seeded inwells of 6-well plates coated with fibronectin, in the ab-
sence or presence of 30% PT45-CM. Cells were allowed to
incubate for 15-19 days at 37°C in a 5% CO2 atmosphere.
Evaluation of acetylated low-density lipoprotein uptake
and of binding to Ulex europaeus lectin, by laser scanning
confocal microscopy (LSCM)
To measure the uptake of acetylated low-density lipo-
protein, and adherence to Ulex europaeus lectin, CD34+
cells were grown in thick-glass-base dishes (Asahi
Techno Glass Co., Singapore). After 15-19 days’ culture
in the presence of IL-3, SCF, and GM-CSF, with or with-
out 30% of PT45-CM, cells were incubated for 1 h at
37°C in RPMI + 10% FCS containing 10 μg/ml 1,1-dioctade-
cyl-3,3,3,3-tetramethylindocarbocyanine-labeled acetylated
low-density lipoprotein (Dil-AcLDL; Molecular Probes,
Eugene, USA) and fixed with 2% paraformaldehyde for
10 min. After washing, fluorescein isothiocyanate (FITC)-
conjugated Ulex europaeus lectin (Sigma Aldrich) was
added at a concentration of 10 μg/ml in PBS, and cells
were incubated for 1 h at room temperature in the dark.
HUVEC were used as positive control. Direct fluores-
cence staining was analyzed by LSCM (Zeiss LSM 510;
Carl Zeiss SpA, Arese, Milan, Italy) equipped with a
Zeiss inverted microscope with a “plan neofluar” lens.
Exciting light intensity, black level, and photomultiplier
gain were adjusted on control specimens; the same set-
tings were used to scan experimental slides. The laser
band of excitation was 488/543 nm; the emission was
set with a 560 nm long-pass filter for Dil-AcLDL (red)
and a 505-530 nm band pass for FITC-conjugated Ulex
europaeus lectin (green). The fluorescent images were
processed using LSCM 510 Image Examiner software
from Zeiss.
Flow cytometry analysis
Expression of endothelial cell markers CD146 and
CD105 was analyzed on untreated and on PT45-CM-
treated CD34+ cells, after 19 days’ culture, in the pres-
ence of GM-CSF, IL-3 and SCF. The cells were stained
with FITC-conjugated CD146 (Chemicon International)
and CD105 (Millipore) mouse monoclonal antibodies
for 30 min at 4°C. After washing, cells were analyzed
by flow cytometry in a Coulter Epics IV Cytometer
(Beckman Coulter, Inc., Fullerton, CA). Results are expressed
as percentages of positive cells. Statistical analyses were
based on at least 30,000 events gated on the population
of interest.
Immunohistochemistry
PT45 cells, and 19-day cultured CD34+ cells in the pres-
ence of IL-3, SCF and GM-CSF, with or without 30% of
PT45-CM, were harvested, cytospinned and fixed in
acetone. After 5 min exposure to 0.3% solution of H2O2,
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treated for 1 h with a blocking buffer (10% normal
mouse/rabbit/goat serum in PBS) to prevent nonspecific
staining, incubated overnight at 4°C with the primary
antibodies listed in Table 2, and then washed twice
with PBS for 5 min each time. For negative controls,
the primary antibodies were replaced with appropriate
non-immune sera. The slides were then treated with ap-
propriate biotinylated secondary antibodies, followed by
incubation with avidin-biotin peroxidase complex solution,
for 30 min, and diaminobenzidine tetrahydrochloride as
chromogen (Dako LSAB® kit, Dako, Glostrup, Denmark).
The slides were finally counterstained with Mayer's
hematoxylin for 5 seconds, dehydrated, and mounted in
Clarion (Biomeda, Foster City, California, USA).
In vitro angiogenesis assays
Matrigel basement membrane matrix (Becton Dickinson,
Franklin Lakes, NJ USA) was added (100 μl) to a 96-well
plate and allowed to polymerize. HUVEC or CD34+
cells, cultured for 19 days in IL-3, SCF and GM-CSF, in
the presence or absence of 30% of PT45-CM, were re-
suspended in Medium 199 (Millipore) and 0.5% FCS
(2×104 cells/1 ml) in the presence of 30% of PT45-CM,
pre-treated or not with neutralizing antibodies against
VEGF or Angio-1, or with the appropriate irrelevant
antibody; they were then plated (100 μl) on the top of
the solidified matrix solution and incubated at 37 C for
24 hr. Tubule formation was visualized using an
inverted-light microscope with a 20X objective (Zeiss),
and images of ten random fields were captured using a
digital camera. Each cell within the optical field was
counted, and this number referred to as the "total num-
ber of cells per field". The angiogenic potential was
quantified from the following formula:
Angiogenic score = [(number of sprouting cells x 1] +
number of connected cells x 2 + number of polygons x
3)]/ Total number of cells per field. The final individual
score derived from the formula was then taken as one
value in a total of ten, with median [range] represented
against other treatment conditions.Table 2 Antibodies and immunohistochemical procedures
Reactivity Antibody Source Antibody
Species Dilution
VEGF-A Rabbit Santa Cruz Biotech., Santa
Cruz, CA
1:20
Angio-1/4 Goat Santa Cruz Biotech 1:200
Angio-2 Goat Santa Cruz Biotech 1:200
CXCL12 Rabbit Santa Cruz Biotech 1:30
VE-cadherin Mouse Santa Cruz Biotech 1:100
vWF related
antigen
Rabbit Shandon Immunon,
Pittsburgh, PA
1:20Statistical analysis
To assess statistically-significant differences between data-
sets, Student's t tests for paired samples, or Mann-Whitney
Rank Sum tests, were performed using SigmaStat software
(Jandel Scientific, San Rafael, CA).Results
Expression of angiogenic factor mRNA in PT45 and in
H6c7 cells by real time RT-PCR
Steady-state angiogenic factor mRNA levels were quanti-
tatively assessed in PT45 and H6c7 cell lines, using real-
time RT-PCR, and normalized gene expressions were
compared (Table 3). Both cell lines expressed similar
levels of VEGF mRNA. Conversely, the Angio-1 tran-
script was expressed at a markedly lower level in H6c7
cells than in PT45 cells (fourteen times lower). Both cell
lines were found to be negative for Angio-2 mRNA. The
CXCL12 message was expressed at a very low level in
PT45 cells and not at all in H6c7 cells.Expression of VEGF-A, Angio-1, Angio-2 and CXCL12
proteins by PT45 and by H6c7 cells
The release of VEGF-A, Angio-1, Angio-2, and CXCL12
proteins was evaluated in PT45-CM and in H6c7-CM by
ELISA. As shown in Figure 1 (upper panel), significantly
higher levels of VEGF-A and Angio-1 were detected
in PT45-CM than in H6c7-CM (mean ± SE: 1413.8 ±
311.6 pg/ml vs. 971.3 ± 186.5 pg/ml, p = 0,042; mean ±
SE: 362.9 ± 37.9 pg/ml vs. 224.4 ± 33.14 pg/ml, p =
0,0267, respectively). Consistently with mRNA expres-
sion, Angio-2 and CXCL12 levels were undetectable by
ELISA in either cell supernatants. Immunohistochemical
analysis of these molecules, run on PT45 cell cytospins
using specific antibodies, detected intense staining for
VEGF-A and Angio-1 in the cytoplasm of the majority
of PT45 cells, while Angio-2 and CXCL12 expression
was negligible (Figure 1, lower panel), consistently with
the ELISA results. The combined expression of VEGF-A
and Angio-1 suggests that the poorly-differentiated
PT45 cells possess higher vascular remodeling capacity
than do H6c7 cells.Table 3 Levels of angiogenic factor mRNA in PT45 and
H6c7 cells
Gene mRNA levels (relative to β-actin)
PT45 cells H6c7 cells
VEGF-A 0,016821a 0,016270
Angio-1 0,000083 0,000006
Angio-2 ndb nd
CXCL12 0,000001 nd
aMean normalized gene expression (MNE).
bnot detectable.
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CD34+?
To test this hypothesis, since production of endothelial
chemotactic factors, such as VEGF-A and Angio-1 [25],
was detected in PT45-CM and in H6c7-CM, the super-
natants were assessed for in vitro chemotaxis of circulat-
ing CD34+ cells, which are known to express the relative
receptors [26]. HUVEC were used as positive controls.
As shown in Figure 2, both HUVEC and CD34+ cells
demonstrated a significant chemotactic response, both
to PT45-CM and to HPDE-CM, although in the latter
case to a lesser extent (CD34+ cells migrated/HPF:
PT45-CM, 16.333 ± 3.082 vs. H6c7-CM, 9.667 ± 3.41,
p = 0.003). Since factors secreted by PT45 and H6c7 cells
are also likely to have an effect on cell proliferation, to
ensure that the results are a true measure of cell
migration, CD34+ cells were cultured for 24 hr in the
presence or absence of PT45-CM or H6c7-CM, and
DNA-synthetic activity was assessed in terms of 3H-TdR
uptake. No significant difference in DNA synthesis
(p >0.05) was observed between untreated and CM-Figure 1 Concentrations of VEGF-A, Angio-1, Angio-2 and CXCL12 in
Values are means ± SE of angiogenic factors detected in duplicate CM samp
(upper panel). Detection of VEGF-A, Angio-1, Angio-2 and CXCL12 in pan
A representative negative control is also shown (original magnification 2treated CD34+ cells [median cpm (range): control 438
(334-527); PT45-CM 395 (296-478); H6c7-CM 380
(297-502)]. In the presence of the mitogenic factors SCF
and FLT-3, the DNA-synthetic activity of CD34+ cells
slightly increased over control values, but not to a
statistically-significant extent (median cpm (range): 531
(344-727) vs. 438 (334-527), p = 0,400). To determine
the factor responsible for chemoattraction of CD34+
cells, the supernatants were pre-treated with isotype-
control or with neutralizing VEGF-A and Angio-1 anti-
bodies. Treatment with antibodies neutralizing Angio-1
activity only partially reduced the CD34+ migration
induced by either CM (% CD34+ cells migration inhib-
ition: PT45-CM, 24.167 ± 8.503%; H6c7-CM, 29.134 ±
13.429%), whereas when the neutralizing VEGF-A
antibody was added, migration was almost entirely
inhibited (% CD34+ cells migration inhibition: PT45-
CM, 75.167 ± 25.87%; H6c7-CM, 59.476 ± 17.359%).
By contrast, exposure to a neutralizing VEGF-R1 poly-
clonal antibody did not significantly decrease CD34+
recruitment (% CD34+ cells migration inhibition: PT45-CM derived from PT45 and H6c7 cell lines measured by ELISA.
les, in five separate experiments for PT45-CM, and in three for H6c7-CM
creatic carcinoma cells PT45, determined by immunohistochemistry.
50X) (lower panel).
Figure 2 Chemo-attraction of CD34+ cells by PT45-CM and H6c7-CM. PB CD34+ cells and HUVEC were seeded into the upper compartment
of a chemotaxis chamber. PT45- or H6c7-CM (30%) was placed in the lower compartment, as such or pre-treated with neutralizing anti-VEGF-A
and anti-Angio-1 antibodies. In selected experiments, CD34+ cells were pre-treated with a neutralizing anti-VEGF-R1 antibody before exposure to
PT45- or to H6c7-CM. After 24 hr incubation, cells in the upper compartment were removed, and the number of CD34+ or HUVEC cells that had
migrated from the upper compartment through the filter into the lower compartment was determined, by counting the cells in three random
high-power fields. (A) Representative images of HUVEC and CD34+ cells migrating in response to medium alone (control), to PT45-CM or to
H6c7-CM, in a transwell migration assay. (B) Number of cells migrating in a transwell migration assay, in the absence or presence of PT45-CM or
H6c7-CM. Results are mean values ± SE of six separate series of studies for PT45-CM and of three series for H6c7-CM. (C) Inhibitory effect of a
neutralizing anti-VEGF-R1 antibody on CD34+ cell chemotaxis; values are expressed as percentage inhibition of CD34+ cell migration in the
presence of PT45-CM/H6c7-CM versus medium alone (control). Data shown are means ± SE from three separate series.
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sion of the isotype control antibodies had no effect
(data not shown). These results demonstrate that, both
in normal and in neoplastic conditions, the chemo-
attractant activity exerted by H6c7 cells on CD34+ cells
is mainly due to VEGF, and that the responding cells
are included in the CD34+/VEGF-R2+ progenitor cell
subset.
Morphological changes of CD34+ cells cultured in the
presence of PT45-CM
The finding that the CD34+ cell subset is recruited by
PT45-CM, along with the higher tumor-derived levels of
VEGF-A and Angio-1 that play prominent roles in thevascularization process, prompted us to investigate
whether tumor cells might cause differentiation of these
CD34+ progenitor cells along the myeloid lineage to be
switched toward the endothelial cell lineage. This was
investigated by culturing purified normal PB CD34+ cells
for 19 days, under experimental conditions recognized
as supporting their differentiation into myeloid cells
(IL-3, SCF and GM-CSF) [27], but in the presence or ab-
sence of PT45-CM. The hypothesis that tumor-CM was
actively altering the differentiation of CD34+ cells was
initially supported by morphological evaluation of the
resulting cells: as shown in Figure 3, in control cultures,
the cells that developed from the CD34+ cells tended to
be rounded. By contrast, in cultures with tumor-CM, a
Figure 3 Altered morphology during differentiation of CD34+
cells in the presence of PT45-CM. Circulating CD34+ cells were
cultured for 19 days in the presence of GM-CSF, IL-3 and SCF, either
in the absence or in the presence of PT45-CM. Shown are represen-
tative examples of cells cultured in GM-CSF, IL-3 and SCF alone (A);
as panel A, but including PT45-CM (B).
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more elongated, spindle-shaped, with areas within the
culture containing cells organized in long head-to-tail
configurations.
Characterization of CD34+ cultured in the presence of
PT45-CM
Tests were then run to determine whether or not endo-
thelial cells develop in cultures containing PT45-CM, by
means of uptake of Dil-AcLDL and Ulex europeus lectin
binding; these activities are characteristic of endothelialcells [28,29]. We assayed these capacities in the 19-day
cultures, by both double immunofluorescence staining
and LSCM. We identified and quantified a small pro-
portion (9-15%) of cells showing double-positive staining
for Dil-AcLDL uptake and binding of Ulex europeus
lectin (Figure 4). These results indicate that this
endothelial-like fraction originates in the hematopoietic
stem-cell-containing CD34+ cell population only in the
presence of tumor-CM.
Quantitative analysis of mRNA expression of VE-cadherin,
vWF, VEGF-R1 and VEGF-R2
Using real timeRT-PCR, the expression of genes corre-
lated with endothelial cell lineage differentiation was
then evaluated, in CD34+ cells cultured for 19 days in
the presence of IL-3, GM-CSF and SCF, with or without
30% PT45-CM. The results, shown in Figure 5, de-
monstrate that VE-cadherin, vWF and in particular
the VEGF-R1 (flt-1) transcripts were more strongly
expressed in CD34+ cells cultivated in the presence of
PT45-CM, versus controls (p = 0.03, p = 0.03 and p =
0.02, respectively). Conversely, the expression of
VEGF-R2 [KDR or flk-1] was not significantly modu-
lated in the presence of PT45-CM.
Expression of endothelial-cell markers on CD34+ cells
cultured in the presence of PT45-CM
Cells derived from CD34+ cells cultured for 19 days with
or without PT45-CM, under conditions that support
myeloid differentiation, were analyzed for endothelial-
cell-marker expression, by flow cytometry (CD146 and
CD105) and by immunohistochemistry (vWF and VE-
cadherin). As shown in Table 4, in the absence of
tumor-CM, a small proportion of cells were positive for
CD146 and CD105. However, when PT45-CM was also
added to the CD34+ cell cultures, a significantly greater
number of cells expressed CD146 and CD105 (p = 0.003
and p = 0.006, respectively,). As shown in Figure 6, ex-
posure to tumor-derived angiogenic factors promoted
the expression of VE-cadherin and vWF, both of which
are endothelial-specific markers, in a subset of cultured
CD34+ cells (24 ± 8% and 23 ± 10%, respectively).
In vitro angiogenesis assays
Using an in vitro angiogenesis assay on Matrigel, the an-
giogenic potential of HUVEC was compared to that of
untreated or PT45-CM-treated CD34+ cells, cultured for
19 days in the presence of IL-3, GM-CSF and SCF.
Figure 7 A-E shows a representative tubulogenesis assay.
On Matrigel, HUVEC formed a well-organized network
of cordlike structures, with a median (range) angiogenic
score of 2.19 (1.29-3.46) (E); conversely, in CD34+ cell
control cultures, no endothelial organization was ob-
served [median (range) angiogenic score: 0 (0-0.02)] (A).
Figure 4 Fluorescence staining of cultured CD34+ cells with Dil-AcLDL and Ulex europeus lectin under an LSCM. Circulating CD34+
cells were cultured for 19 days in the presence of GM-CSF, IL-3 and SCF, either without or with PT45-CM. The laser band of excitation was 488/543 nm;
the emission was set with a 560 nm long-pass filter for Dil-AcLDL (red) and a 505–530 nm band pass for FITC conjugated Ulex europeus lectin (green).
Photographs are from one representative experiment. The lens used was 20×/0.5 (0.849 × 0.849 mm2 image dimension). The fluorescent images
were processed using an LSCM 510 Image Examiner Program from Zeiss: the yellow merged image represents the result of double-fluorescence
labeling.
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sions, connections, and alignments, but tube formation was
less pronounced [median (range) angiogenic score of 1.47
(0.98-1.70), p = 0,002 vs. HUVEC and p < 0.001 vs. CD34+
control cells] (B). The formation of capillary-like structures
by PT45-CM treated CD34+ cells was significantly reduced
by the use of a neutralizing anti-Angio-1 antibody [medianFigure 5 Levels of VE-cadherin, vWF, VEGF-R1 and VEGF-R2
mRNA in CD34+ cultured with or without PT45-CM. Cells were
cultured for 19 days under conditions supporting their
differentiation toward myeloid lineage cells, in the presence or
absence of PT45-CM. Results were assessed by real time RT-PCR, and
normalized to β-actin mRNA levels. Normalized gene expression
values relative to that of control CD34+ cells (cultured in the absence
of PT45-CM, arbitrarily set to 1) are shown.(range) angiogenic score of 0.45 (0-1), p < 0.001 vs. PT45-
CM-exposed CD34+ cells] (C), but not when PT45-CM
was pre-treated with a neutralizing anti-VEGF-A antibody
[median (range) angiogenic score of 1.39 (0.20-1.72),
p = 0.345 vs. PT45-CM exposed CD34+ cells] (D). Non-
immune goat IgG did not affect cell organization (not
shown).
Discussion
Expression of the CD34 surface antigen characterizes a
heterogeneous population of BM-derived cells, including
hematopoietic progenitor cells (HPC) and EPC [30],
which can differentiate into mature endothelial cells
when recruited to angiogenic sites. This in situ develop-
ment of vessels, known as vasculogenesis, is prominent
during embryonic development. However, although tis-
sue remodeling and regeneration in postnatal life are
mainly due to angiogenesis, involving preexisting vessels,
it has recently been found that also vasculogenesis can
occur in the adult, particularly during wound healing
and tumor vascularization [31,32]. In cancer patients, in-
cluding those with advanced pancreatic carcinoma, EPC
are numerous compared to healthy controls; EPC num-
bers also correlate positively with circulating VEGF-A
levels, and inversely with disease stage and prognosis
[17,33,34]. These findings combine to suggest that tumor
microenvironmental conditions may foster the recruit-
ment, mobilization, and differentiation of EPC [35]. Both
Table 4 Flow cytofluorimetric analysis of endothelial
marker CD146 and CD105
Colture conditions
of CD34+ cells
% positive cells (mean ± SE)
CD146 pa CD105 p
GM-CSF, IL-3, SCF 12.14 ± 5.9 18.14 ± 3
GM-CSF, IL-3, SCF +
30% PT45-CM
21.84 ± 7.7 0.003 28.1 ± 2.1 0.006
avs CD34+ cultured in the presence of IL-3, GM-CSF and SCF.
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cells, locally secrete a broad spectrum of biologically-
active factors that facilitate cancer growth.
In a previous study that examined an array of tumor-
derived cytokines affecting the immune response, we
found that the poorly-differentiated pancreatic carcin-
oma cell line PT45 produced high levels of VEGF-A
[10]. The present study shows that, among other rele-
vant angiogenic factors including the angiopoietins andFigure 6 Detection by immunohistochemistry of VE-cadherin and vW
cultured for 19 days under conditions supporting their differentiation towa
Specimens are representative examples of nine different experiments. RepreseCXCL12, PT45 cells also express Angio-1 mRNA and
protein. However, these vasculogenic cytokines are not
tumor-exclusive products, but are thought to be part of
the complex milieu involved in maintaining the vascula-
ture in normal tissues: they are also expressed, albeit to
a lesser extent, in the near-normal HPDE H6c7 cells.
VEGF-A, released by both malignant (PT45) and normal
(H6c7) cells, appears to play a major role, with regard to
cell targets (CD34+ VEGF-R2+) and functional chemo-
tactic activity.
Unlike the physiological restoration of vascular perfu-
sion to damaged tissues, blood vessel development in
solid tumors is not closely controlled, but continues re-
lentlessly. Tumors exploit a number of strategies to
achieve vascularization (alteration of local normal equi-
librium of anti and pro-angiogenic stimuli, co-optation
of pre-existing vessels, stimulation of intussusceptive
microvascular growth, post-natal vasculogenesis, and/orF in CD34+ cells cultured with or without PT45-CM. Cells were
rd myeloid lineage cells, in the presence or absence of PT45-CM.
ntative negative controls are also shown (original magnification 250X).
Figure 7 In vitro angiogenic potential of PT45-CM treated CD34+ cells. CD34+ cells were grown on Matrigel for 24 h, after being cultured
for 19 days under conditions supporting their differentiation toward myeloid lineage cells, in the absence (A) or presence (B) of PT45-CM, pre-
treated or not with a neutralizing anti-Angio-1 antibody (C) and with a neutralizing anti-VEGF-A (D) antibody. HUVEC (E) were used as positive
control. The figure is representative of three experiments done in duplicate; the results are presented as median (range) values of the angiogenic
numerical score, derived from the formula reported in the Materials and Methods section.
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quences on tumor growth, metastasis, and response to
therapy. It thus appears possible that pancreatic tumor
cells, influenced by their microenvironment, might also
exploit abnormal levels of normally-beneficial angiogenic
factors, such as VEGF and Angio-1, as one strategy to
achieve vascularization.The present study shows that, presumably thanks to
an abnormally elevated gradient of angiogenic growth
factors, medium conditioned by PT45 pancreatic carcin-
oma cells affects differentiation of a subset of CD34+
cells into endothelial cells, producing conditions that
support their differentiation toward myeloid lineage cells
[27]. It is well-known that the high levels of VEGF
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in the peripheral circulation, and enhance their recruit-
ment to the tumor vasculature [37,38]. Moreover,
Angio-1 modulates several aspects of angiogenesis, in-
cluding remodeling and vascular permeability, and, in
conjunction with VEGF, it also plays an essential role in
promoting the survival of endothelial and hematopoietic
progenitor cells [39]. We show here the existence of a
subpopulation of CD34+ cells (10-15%) that, cultured
under pro-myeloid differentiative conditions in the pres-
ence of PT45-CM, acquire what are often referred to as
“endothelial cell lineage markers”, namely spindle shape,
incorporation of Dil-AClDl, and binding to Ulex-lectin
[28,29]. This suggests that, among CD34+ cells, endothe-
lial stem cells/progenitor cells may exist. In general,
early EPC in the BM, or immediately after their migra-
tion into the systemic circulation, are positive for
CD133/CD34/VEGF-R2, whereas circulating EPC are
positive for CD34/VEGF-R2/CD31 [40]. This indicates
that at least two types of EPC are simultaneously present
in the peripheral blood, and that the cells can change
their progenitor properties while in the circulation.
However, since purified CD34+ cells were concomitantly
cultured in the presence of IL-3, SCF and GM-CSF (all
of which are survival and/or myeloid differentiation fac-
tors) it cannot be ruled out that these cells might origin-
ate from the monocyte/macrophage lineage, as other
reports have suggested [41,42]. Although it has been
suggested that myeloid cells may express specific endo-
thelial markers (such as CD34, CD31 and VEGF-R2),
and that they may localize adjacent to blood vessels, and
differentiate into endothelial cells [43,44], this hypothesis
remains controversial; further research will be needed to
clarify the situation.
In the present study, mRNA of both Flt-1 and KDR
(genes encoding, respectively, for VEGF-R1 and VEGF-
R2) were detected in untreated CD34+ cells. After
19 days’ culture in the presence of IL-3, SCF and GM-
CSF, with 30% PT45-CM, the Flt-1 transcript signifi-
cantly increased, while KDR was unchanged. In a study
on angiogenic-defective tumor-resistant Id-mutant mice,
the restoration of tumor angiogenesis, after transplant-
ation of wild-type BM or VEGF-mobilized stem cells,
was associated not only with the uptake of BM-derived
VEGF-R2+-endothelial precursor cells in the blood
vessels, but also with the incorporation of BM-derived
myeloid cells into perivascular sites of the tumor micro-
environment, these cells being characterized by the
expression of VEGF-R1 [45]. It has been suggested that
VEGF-R1+ cells may differentiate into pericyte-like cells
and play a role similar to pericytes in the tumor
microenvironment [46].
It may, thus, be speculated that VEGF release by PT45
cells might concomitantly promote CD34+ VEGF-R2+cell differentiation along the endothelial lineage, this dif-
ferentiation being characterized by the expression of
vWF and VE-cadherin [47]. VEGF release might also in-
duce the appearance of pericyte-like CD34+ VEGF-R1+
cells, which play mutually-supporting roles in tumor-
vessel neoformation and stabilization, respectively. This
hypothesis is supported by the finding that, after expos-
ure for 19 days to PT45-CM in the presence of IL-3,
SCF and GM-CSF, some CD34+ cells began to express
specific endothelial markers, namely CD146, CD105,
VE-cadherin and vWF, and a subset of cells started to
express VEGF-R1 RNAm. Interestingly, in human tissues
from patients with malignancies, VEGF-R1+ cell clusters
have been observed in both primary tumor and meta-
static tissue; increased numbers of VEGF-R1+ clusters
have also been found at common sites of metastasis even
before tumor spread, suggesting this tissue might be a
potential future site for metastasis [48]. PT45 cells also
produce and release Angio-1, the natural ligand for tu-
nica internal endothelial cell kinase (Tie)-2 receptor, [49]
which, in conjunction with VEGF, modulates some as-
pects of angiogenesis, including remodeling and vascular
permeability [50].
In our study, a subset of CD34+ cells, cultured under
conditions that support their differentiation toward mye-
loid lineage cells, acquired expression of Tie-2 (data not
shown) whether or not the culture medium comprised
PT45-CM. Interest in cells of the myeloid lineage in re-
gard to tumor angiogenesis has recently been revived,
thanks to the observation that tumor-infiltrating Tie-2-
expressing monocytes (TEM) convey pro-angiogenic
programs in mouse models. TEM preferentially reside
around newly formed tumor blood vessels in viable
tumor areas [51,52]. It may thus be speculated that
tumor-derived Angio-1 not only has a direct effect on
endothelial cell behavior during vascular remodeling,
but may also play a role in maintaining interactions
between endothelial cells and support cells.
Since completing the tumor vasculogenesis process in-
volves aligning endothelial cells and forming a three-
dimensional network of tubes incorporating a functional
microvasculature, it was also evaluated whether CD34+
cultured in Matrigel, in the presence of IL-3, SCF and
GM-CSF with or without PT45-CM, could organize into
a capillary-like structure. CD34+ cells, pre-exposed to
PT45-CM, appeared markedly flattened; they migrated
throughout the Matrigel surface and formed a network
of interconnecting cells. Conversely, non-pre-exposed
CD34+ cells were small, round in shape, and did not
spread. The fact that the introduction of an anti-Angio-1
blocking antibody caused the CD34+ cells to remain
grouped suggests that Angio-1, released by PT45 cells, fa-
vors the formation of capillary-like structures, while VEGF-
A apparently has no effect on endothelial organization.
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vasculogenesis to cancer progression are whether EPC
are mobilized in response to cytokine release, either by
tumor cells or by damaged tissues/host immune cells,
and whether the role of EPC in angiogenesis is merely
regulatory, or whether they form part of the new tumor
vasculature [53]. Our study shows that circulating EPC
may be chemo-attracted, and develop into endothelial-
like cells that can form cord-like structures in vitro,
under the direction of factors released by pancreatic
tumor cells. This might clarify the processes whereby
pancreatic-tumor-mobilized EPC contribute to vessel
formation, and in any case adds a possible explanation
for the observation of increased circulating EPC in pan-
creatic carcinoma [10].
Blocking recruitment of EPC may be essential in order
to overcome their negative consequences in terms of pa-
tient survival. Preclinical and clinical evidence suggests
an association between treatment with certain drugs
(including 5-fluouracil, the drug most commonly used to
treat advanced/metastatic pancreatic cancer) and in-
creased levels of BM-derived EPC and VEGF-R1+ cells;
these cells stimulate tumor progression and metastasis
[54-56]. Other conventional drugs, such as gemcitabine
and cisplatinum, show no similar association [57].
Numerous clinical trials employing antiangiogenic
drugs for the treatment of pancreatic cancer have thus
far failed to produce improvements in treatment [58].
One of the possible mechanisms underlying this general
resistance is poor tissue perfusion, which limits drug de-
livery. Olive et al. provided evidence that, in KRAS and
p53 mutant pancreatic adenocarcinoma xenografts in a
gemcitabine-resistant mouse model, chemotherapy does
not reach tumor cells due to poor tumor vascularization
[59]. Approaches involving antiangiogenic therapy are
thus counterintuitive, given that destruction of the
tumor vasculature might be expected to impair drug
delivery.
Pancreatic carcinoma is generally surrounded by dense
fibro-inflammatory tissue that creates unusually high
interstitial fluid pressure (IFP); this high pressure col-
lapses the tumor blood vessels, limiting access by, and
efficacy of, conventional forms of chemotherapy [60].
In genetically-engineered mouse models of pancreatic
adenocarcinoma, which mimic the clinical syndrome,
histopathology, and molecular progression of the human
disease, combined enzymatic degradation of hyaluronan
and cytotoxic therapy leads to a rapid reduction of the
IFP, accompanied by remodeling of the standard cyto-
toxic delivery; this combined approach thus holds prom-
ise as a therapeutic strategy [61].
On the basis of these studies, and in consideration of
the complex role of tumor vascularization in rela-
tions between chemotherapic drugs and tumor cells,treatment approaches involving targeting angiogenesis
and vasculogenesis should be evaluated with extreme
care.
Conclusions
This study demonstrates the ability of pancreatic carci-
noma cells to attract CD34+ cells to the tumor site, and
to interfere with those cells' hematopoietic development,
by diverting their differentiation toward endothelial cells;
these cells can become a component of the tumor vas-
culature. A better understanding of cancer-associated
molecular mechanisms involved in favoring the vasculo-
genesis process in pancreatic carcinoma could therefore
provide important knowledge to design new and more
effective ways of combining anti-angiogenic drugs with
established chemotherapies, the goal being to prevent
angiogenic escape or invasion.
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